Institute for Stem Cell Biology and Regenerative Medicine
Research in the Majeti Lab

Ravindra Majeti focuses on the molecular characterization and therapeutic targeting of leukemia stem cells in human hematologic disorders, particularly acute myeloid leukemia (AML). The Majeti lab is also interested in developing a similar characterization of normal human hematopoiesis and hematopoietic stem cells. A major focus of the lab is the identification of cell surface molecules preferentially expressed on leukemia stem cells and the development of therapeutic monoclonal antibodies targeting these proteins. Toward this goal, together with Irv Weissman, the lab is actively developing an anti-CD47 antibody for clinical trials in human AML.

 

Recent Publications

CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD, van Rooijen N, Weissman IL. Cell. 2009; 138 (2): 286-99

.

Dysregulated gene expression networks in human acute myelogenous leukemia stem cells. Majeti R, Becker MW, Tian Q, Lee TL, Yan X, Liu R, Chiang JH, Hood L, Clarke MF, Weissman IL. Proc Natl Acad Sci U S A. 2009; 106 (9): 3396-401

 


All Publications >>

 

 

 
Lab info
What's new

Stanford Medicine Resources:

Footer Links: